Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Short-Sellers Shy Away From These 2 Biotechs This Settlement Period
Celgene Reports Second-Quarter Results, Highlights 'Outstanding' 2016 Performance
3 Big Drugmakers That Beat Wall Street Q2 Estimates Thursday (Investor's Business Daily)

In a report published Friday, Jefferies reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $104.00 to $114.00.

Jefferies noted, “On its 4Q earnings call, CELG focused details around achieving the 2017 guidance laid out earlier this month. We are raising our price target from $104 to $114 as we are adding modest apremilast to our valuation and raising our expectations for Abraxane penetration in pancreatic cancer following positive Phase 3 data released yesterday.”

Celgene Corporation closed on Thursday at $97.49.

Latest Ratings for CELG

DateFirmActionFromTo
Jul 2016Stifel NicolausInitiates Coverage onBuy
Jun 2016BTIG ResearchDowngradesBuyNeutral
Apr 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!